Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice - Wikidata - awgldk - TriplyDB

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

http://www.wikidata.org/entity/Q35804816

about

Ischemic stroke injury is mediated by aberrant Cdk5 Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy Corticostriatal Dysfunction in Huntington's Disease: The Basics Dopamine Receptors and Neurodegeneration Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases Modeling Huntington's disease with induced pluripotent stem cells Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutation Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms.Expression analysis of novel striatal-enriched genes in Huntington disease.Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain.Alterations in the mouse and human proteome caused by Huntington's disease.A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Tetrabenazine is neuroprotective in Huntington's disease mice.Laquinimod treatment in the R6/2 mouse model.A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease.Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington's disease.Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.

P2860

Q23912228-5394BC07-0569-4A60-BD46-98E827D5768B Q24307769-917F5BE7-CFF2-4281-99CD-FDD873EBDDB7 Q26738379-C0C08A29-01C4-42FA-9D67-BE27772D9D8E Q26783348-D10ED258-0456-4002-99F6-9F38CD17AC98 Q26830654-44D68843-ADD1-4EA3-9FEA-F3C7B0F46308 Q27004209-2977DCF0-DB66-4B75-90D5-403F0D37D190 Q27305680-0B4BD242-DE99-44AE-845D-13F9BAD27969 Q27306293-F6E20213-F9C8-4BA9-B46D-388AE6B8BF5F Q27309160-37864BB4-B3C9-4D8A-835A-CA2662814EC3 Q28282315-1DE254DB-0BD9-4AE7-B3D7-53FF13B27EEF Q28479035-DEB69F39-EAC9-4ADE-BC5A-37C2A77F8763 Q28510296-10B39ADD-7BF9-4F82-9EBD-BF37864117F0 Q28569506-55861483-CF43-49DC-BD37-419EB2A9EF39 Q28728849-AA78F9CA-6503-401B-AE58-6F072653DD69 Q30406678-1BD838A2-3E47-4DE4-82BF-2C5338C8D4AE Q30437914-9678119F-ACB2-4C0E-944A-8EF3A141585C Q30441124-518B3C3E-D6EB-4E90-8DD1-2F9D3C8B950E Q30476999-4299D675-E930-4D75-AA0B-DD42D54FE017 Q30506469-222982F8-A59C-46E9-9CEF-3A8C017B52A7 Q30838090-8BDD6228-167C-449A-804E-A4DA719E4378 Q31096639-1AF6EC05-8E95-4E1D-9C05-367E19879DEB Q33640604-2B490B90-5E09-46FC-82C5-948F7FC4296C Q33863426-63C38839-41E4-41D4-B32F-1B5585742294 Q33890346-29065932-248A-4163-8A01-C580CA572350 Q33920945-3A6D952D-5BB4-4E6C-9506-C4607EC1BFF1 Q33931283-A00784F3-0EDF-4195-9DC4-18E4C025C5A2 Q33980357-32FB7C2C-F815-4D74-8AD4-9227439F6918 Q34017941-508EDC2D-D17E-4A62-8BD2-2EC16471F1DC Q34075502-DD00AA52-5282-4751-A99A-35E8694EE75B Q34152284-C612EE36-9BB6-49D9-8854-42B37DA777D1 Q34212651-7DD60C2E-725C-4510-84A1-98AA168793D4 Q34271560-31C09F4B-F96F-40E1-9BEE-2D53BCD3C990 Q34391101-284B666C-D0D7-4E40-BC98-A2F1C8F315CF Q34459323-127989C1-66C1-4F36-8E35-CABCC79C72B6 Q34531481-07175B5D-C929-40D0-AB8A-44C42A9AEE84 Q34689527-A41AF1EA-4137-4354-B12F-FC1C14D4BBF7 Q34699467-BB01A6A5-CA95-47DD-B10A-C117E598F4F7 Q34926634-72C17952-6019-4E91-B2EC-952C1682727D Q34994779-11A2F7D3-8AEF-4746-8C65-C7F09D7F8FC2 Q35049600-7952C4A5-3AB8-49AE-B884-0387269BA743

P2860

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

http://www.wikidata.org/entity/Q35804816

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@ast

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@en

type

label

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@ast

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@en

prefLabel

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@ast

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@en

P1433

Q35804816-BA82516E-B8BE-4506-9732-99FEA8F6B023

P1476

Q35804816-FF1F0858-03F4-4485-8BC6-E8D87F726108

P2093

Q35804816-3B5117BA-3DA9-43A8-B603-65C74E0C0EFB

Q35804816-4E25126A-9067-491B-B664-75AE37DAED1D

Q35804816-52B30EA4-90AF-4A9F-88CA-99223D0A237F

Q35804816-614CF074-14C4-47FB-A2B1-F7BB06115A68

Q35804816-A4E0A4A4-DC16-4491-BA3B-70E842AB0A40

Q35804816-AA453AB7-B830-49FC-87F3-6C22369203E0

Q35804816-BF0F309E-5EA0-4F6F-9CCE-7FA0347982B6

P2860

Q35804816-1578C4FC-93E8-4275-A50F-3B6B3400D7F3

Q35804816-16D1FDDC-BF2B-49C0-A732-EDAA1B778207

Q35804816-1FC206D6-C4AA-4DF4-B354-AE3BC76B2950

Q35804816-40F735BD-1F22-4529-A257-4F2A1C76A21B

Q35804816-45ADBAC5-3BFA-4F14-9522-91AA6D1BC276

Q35804816-48B098E2-0079-4733-87D7-4AEF51B681C8

Q35804816-51F172C5-B75A-4290-BA2D-4457F12354E3

Q35804816-59DCCC5B-8D6F-4241-92E6-E28CF20E5C82

Q35804816-5D5BC7C8-78F9-4FB9-A9D1-25BED06A7199

Q35804816-64B4ADD9-0105-4B61-A056-1413E4016968

P304

Q35804816-B08A6304-8BE2-4318-B877-8B40B2088E9B

P31

Q35804816-CCD269FF-E4EB-4471-ABDA-9801ED87A4CF

P356

Q35804816-19CECCA2-27FA-4BF0-BD9F-DA037073EA62

P407

Q35804816-EC49383A-8972-4B5B-822F-8CB213B416C4

P433

Q35804816-55D9BFD8-9737-408A-BB19-B2D0B68ADE20

P478

Q35804816-96AE56AA-7119-41D5-9B6D-3FD7C18A94C1

P50

Q35804816-0142E2C4-68A3-4C2F-A1E6-EBA5E4C2E8EB

Q35804816-53D4DC48-BC30-4779-B2A6-BB9660A6C4BF

P577

Q35804816-69F677BF-0EAE-4A52-82BD-8E39E96EA890

P5875

Q35804816-96451CA8-A2DF-4565-B7E2-1EA2B41AFEB2

P698

Q35804816-A6E0756F-A167-4DE5-91A2-6F8D4B426070

P921

Q35804816-4CAA2DBA-7C88-41DA-AB60-DE79770DE776

P932

Q35804816-07D20E44-C5CA-4A1F-B401-31E0B02E173F

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

@en

P2093

A C Nairn

http://www.w3.org/2001/XMLSchema#string

A Horiuchi

http://www.w3.org/2001/XMLSchema#string

A Messer

http://www.w3.org/2001/XMLSchema#string

G L Snyder

http://www.w3.org/2001/XMLSchema#string

J A Bibb

http://www.w3.org/2001/XMLSchema#string

V A Pieribone

http://www.w3.org/2001/XMLSchema#string

Z Yan

http://www.w3.org/2001/XMLSchema#string

P2860

Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches

DARPP-32: regulator of the efficacy of dopaminergic neurotransmission

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Synapsins: mosaics of shared and individual domains in a family of synaptic vesicle phosphoproteins

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

Rat DARPP-32: cloning, sequencing, and characterization of the cDNA.

Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade.

P304

6809-6814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.120166397

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Per Svenningsson

P577

2000-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12489212

http://www.w3.org/2001/XMLSchema#string

P698

10829080

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

18747

http://www.w3.org/2001/XMLSchema#string